AI Article Synopsis
- This study investigates the effects of JNJ-54175446, a selective P2X7 receptor antagonist, on mood and neuroinflammation in a clinical trial.
- At doses of 100 mg or higher, JNJ-54175446 was well tolerated and showed promise in both reducing pro-inflammatory cytokines and enhancing the mood benefits of dexamphetamine.
- The results suggest that this drug may have potential as a mood-modulating treatment, indicating a different dosage might be needed for effects on the brain compared to its peripheral actions.
Article Abstract
Background: This is the first report of the pharmacodynamic (PD) effects of the selective, potent and brain-penetrant P2X7 receptor (P2X7R) antagonist JNJ-54175446. Activation of the P2X7R, an adenosine triphosphate-gated ion channel, leads to the production of pro-inflammatory cytokines, which have been linked to neuroinflammation and play a role in the pathogenesis of mood disorders. Previous clinical studies with JNJ-54175446 demonstrated peripheral target engagement of JNJ-54175446 by assessing ex vivo lipopolysaccharide (LPS)-stimulated cytokine production. Blood-brain barrier penetration and a clear dose-receptor occupancy relationship was demonstrated using positron emission tomography.
Aims: The objectives of this double-blind, placebo-controlled, translational study were to assess the safety and tolerability of administering multiple doses of JNJ-54175446 and to explore its PD effects using a dexamphetamine challenge.
Methods: Subjects ( = 64) were randomised to either JNJ-54175446 (50-450 mg; = 48) or placebo ( = 16) and underwent a baseline oral 20 mg dexamphetamine challenge followed by 11 consecutive days q.d. dosing with JNJ-54175446/placebo and a randomised crossover dexamphetamine/placebo challenge.
Results: At all doses tested, JNJ-54175446 was well tolerated and suppressed the ex vivo LPS-induced release of cytokines. At doses ⩾100 mg, JNJ-54175446 attenuated dexamphetamine-induced increases in locomotion and enhanced the mood-elevating effects of dexamphetamine, suggesting that a dose that is approximately twice as high is needed to obtain a central PD response compared to the dose needed for maximum peripheral occupancy.
Conclusion: Overall, the observed pharmacological profile of JNJ-54175446 in the dexamphetamine challenge paradigm is compatible with a potential mood-modulating effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0269881120914206 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period.
Am J Obstet Gynecol
July 2024
Department of Obstetrics & Gynaecology, UBC, Vancouver, BC, Canada; Reproductive Mental Health Program, BC Women's Hospital, Vancouver, BC, Canada; BC Women's Health Research Institute, Vancouver, BC, Canada; University of Calgary, Calgary, AB, Canada. Electronic address:
Attention-deficit/hyperactivity disorder is a childhood-onset neurodevelopmental disorder that frequently persists into adulthood with 3% of adult women having a diagnosis of attention-deficit/hyperactivity disorder. Many women are diagnosed and treated during their reproductive years, which leads to management implications during pregnancy and the postpartum period. We know from clinical practice that attention-deficit/hyperactivity disorder symptoms frequently become challenging to manage during the perinatal period and require additional support and attention.
View Article and Find Full Text PDFCharacterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.
Transl Psychiatry
July 2023
Centre for Human Drug Research, Leiden, the Netherlands.
JNJ-54175446 is a selective purine P2X7 receptor (P2X7R) antagonist that attenuates microglial IL-1β/IL-18 release. In healthy volunteers, JNJ-54175446 suppressed peripheral interleukin (IL)-1β release, and attenuated dexamphetamine-induced improvements of mood and (visuo)motor performance in a human dexamphetamine-challenge paradigm. In depression, P2X7R inhibition may dampen immune-related dysregulation of mood.
View Article and Find Full Text PDFDevelopment of Child-Friendly Lisdexamfetamine Chewable Tablets Using Ion Exchange Resin as a Taste-Masking Carrier Based on the Concept of Quality by Design (QbD).
AAPS PharmSciTech
June 2023
China State Institute of Pharmaceutical Industry, 285 Gebaini Road, Shanghai, 201203, China.
Taste masking is critical to improving the compliance of pediatric oral dosage forms. However, it is challenging for extremely bitter lisdexamfetamine dimesylate (LDX) with a long half-life and given in large dose. The present study aims to develop an immediate-release, taste-masked lisdexamfetamine chewable tablet.
View Article and Find Full Text PDFBrain Serotonin Release Is Reduced in Patients With Depression: A [C]Cimbi-36 Positron Emission Tomography Study With a d-Amphetamine Challenge.
Biol Psychiatry
June 2023
Invicro, London, United Kingdom; Department of Neuroimaging, King's College London, London, United Kingdom.
Background: The serotonin hypothesis of depression proposes that diminished serotonergic (5-HT) neurotransmission is causal in the pathophysiology of the disorder. Although the hypothesis is over 50 years old, there is no firm in vivo evidence for diminished 5-HT neurotransmission. We recently demonstrated that the 5-HT receptor agonist positron emission tomography (PET) radioligand [C]Cimbi-36 is sensitive to increases in extracellular 5-HT induced by an acute d-amphetamine challenge.
View Article and Find Full Text PDFAmphetamine-induced dopamine release and impulsivity in Parkinson's disease.
Brain
October 2022
Department of Neurology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Impulsive-compulsive behaviours manifest in a substantial proportion of subjects with Parkinson's disease. Reduced ventral striatum dopamine receptor availability, and increased dopamine release is noted in patients with these symptoms. Prior studies of impulsivity suggest that midbrain D2 autoreceptors regulate striatal dopamine release in a feedback inhibitory manner, and in healthy populations, greater impulsivity is linked to poor proficiency of this inhibition.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!